Shots:

• The P-III (DESTINY-Breast06) study investigates the safety & efficacy of Enhertu (5.4mg/kg) vs CT (capecitabine, paclitaxel or nab-paclitaxel) for the treatment of HR+, HER2 low or ultralow advanced or metastatic breast cancer
• The study demonstrated improved PFS among HER2 low & ultralow metastatic breast cancer patients. Subgroup analysis confirmed consistent improvement in PFS across both HER2 expression groups
• The OS data was immature during the analysis but an early trend in its improvement was established among HER2 low metastatic breast cancer patients & overall population. Further OS & 2EPs evaluation will continue as planned with the results anticipated at future conferences. Plans for regulatory submissions worldwide are underway

Ref: Daiichi Sankyo | Image: Daiichi Sankyo

Related News:- AstraZeneca and Daiichi Sankyo’s Enhertu Receives the US FDA’s Accelerated Approval to Treat Metastatic HER2-Positive Solid Tumors

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com